Vnitr Lek 2017, 63(4):289-291 | DOI: 10.36290/vnl.2017.058

Antikoagulační terapie dabigatranem vs rivaroxabanem u seniorů ve věku nad 65 let: porovnání dat "head to head"

Martin Polák
JIP interních oborů Interního oddělení Oblastní nemocnice Příbram, a.s.

Received: March 21, 2017; Published: April 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Polák M. Antikoagulační terapie dabigatranem vs rivaroxabanem u seniorů ve věku nad 65 let: porovnání dat "head to head". Vnitr Lek. 2017;63(4):289-291. doi: 10.36290/vnl.2017.058.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Čihák R, Haman L, Táborský M et al. Doporučené postupy ESC 2016 pro léčbu fibrilace síní formulované ve spolupráci s EACTS. Cor et vasa 2016; 58(6): 728-771. Go to original source...
    2. Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the Management of Atrial Fibrillation dveloped in Collaboration with EACTS. Europace 2016; 18(11): 1609-1678. Go to original source... Go to PubMed...
    3. Graham DJ, Reichman ME, Wernecke M et al. Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation. JAMA Intern Med 2016; 176(11): 1662-1671. Go to original source... Go to PubMed...
    4. Schaefer JK, McBane RD, Wysokinski WE. How to Choose Appropriate Direct Oral Anticoagulant for Patient with Nonvalvular Atrial Fibrillation. Ann Hematom 2016; 95(3): 437-449. Go to original source... Go to PubMed...
    5. Shenasa M, Camm JA. Management of Atrial Fibrillation. Oxford University Press: Oxford 2015. ISBN 978-0-19-968631-5.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.